A team of University of Kentucky Markey Cancer Center researchers has found the mechanism that grants prostate cancer resistance to enzalutamide, a frequently used drug. The article is published ...

A combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive ...